India’s Supreme Court has denied Novartis AG’s request for patent protection for its Gleevec cancer treatment, allowing the nation’s generic drugmakers to continue to sell copies of the drug at a lower price.
In a decision watched by non-profit groups seeking to expand access to medicines and drugmakers concerned about India’s position on intellectual property, the court upheld regulatory rulings dating to 2006 that the drug wasn’t sufficiently innovative...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team